Meloxicam Lador Empifarma - Produtos Farmacêuticos

Meloxicam, the active ingredient in Meloxicam Lador Empifarma, is a non‑steroidal anti‑inflammatory drug presented as an oral tablet for oral use. It reduces inflammation and pain associated with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute musculoskeletal pain in adult patients.

GNH USA supplies Meloxicam Lador Empifarma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meloxicam is an NSAID indicated for several inflammatory and musculoskeletal conditions. - Osteoarthritis: reduces joint pain and improves function in patients with degenerative joint disease. - Rheumatoid arthritis: alleviates inflammatory pain and swelling in chronic autoimmune arthritis. - Ankylosing spondylitis: decreases spinal inflammation and stiffness in patients with axial spondyloarthritis. - Acute pain: provides short‑term relief of moderate to severe pain from injuries or postoperative settings.

Meloxicam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Gastrointestinal discomfort: nausea, dyspepsia or abdominal pain. - Headache: mild to moderate intensity. - Peripheral edema: mild swelling of the lower limbs.

Serious or Rare Side Effects: - Peptic ulcer disease or gastrointestinal bleeding. - Severe hepatic injury: elevated liver enzymes or jaundice. - Renal impairment: acute kidney injury or worsening of chronic kidney disease.

When prescribing meloxicam, several precautions should be observed to minimize risk. - Assess renal function: avoid use in patients with severe renal impairment. - Monitor hepatic enzymes: use cautiously in liver disease. - Evaluate cardiovascular risk: consider alternatives in patients with history of myocardial infarction. - Use with caution in the elderly: increased susceptibility to gastrointestinal adverse events. - Avoid concurrent use with other NSAIDs or COX‑2 inhibitors: heightened risk of toxicity. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Meloxicam can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of serious bleeding. - Selective serotonin reuptake inhibitors (SSRIs) or SNRIs: heightened gastrointestinal bleeding risk. - Lithium: meloxicam may raise lithium serum concentrations.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may reduce renal function, especially in volume‑depleted patients. - Diuretics: potential for decreased renal clearance. - Methotrexate: possible increased toxicity due to reduced renal excretion.